Accessibility Menu
Abrdn Life Sciences Investors logo

Abrdn Life Sciences Investors(NYSE) HQL

Current Price$19.77
Market Cap$599.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)+2,300%
5 Year+63%
1 Year+68%
1 Month+8%
Abrdn Life Sciences Investors last closing stock price
MetricPriceDate
Last closeUSD 19.722026-07-22
Abrdn Life Sciences Investors stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.13%USD 20.152026-07-15
1 month+7.52%USD 18.342026-06-22
3 month+16.98%USD 16.862026-04-23
Year to date+25.4%USD 15.732025-12-31
1 year+68.07%USD 11.732025-07-22
3 year+109.16%USD 9.432023-07-21
5 year+63.4%USD 12.072021-07-23
Since inception+2,299.66%USD 0.821992-05-01

Abrdn Life Sciences Investors Financials at a Glance

Market Cap

$599.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$79.82M

Net Income (TTM)

$185.97M

EPS (TTM)

$6.68

P/E Ratio

2.95

Dividend

$2.04

Beta (Volatility)

0.75 (Low)

Price

$19.77

Volume

7,209

Open

$19.92

Previous Close

$19.77

Daily Range

$19.58 - $19.92

52-Week Range

$13.01 - $21.32

Estimated Earnings Date

Jun 24, 2025

HQL News

The Best ETF for 2007: H&Q Life Sciences Investors

Jim FinkNov 16, 2006

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Abrdn Life Sciences Investors

Tekla Life Sciences Investors is a closed-ended equity mutual fund managed by Tekla Capital Management LLC. The fund focuses on investment opportunities in the life sciences sector, targeting growth-oriented companies worldwide.

Products and Services
  • Invests in biotechnology, pharmaceuticals, and medical devices
  • Focuses on small market capitalization growth companies
  • Utilizes rigorous fundamental analysis for investment decisions
Growth Outlook
  • Recent quarterly revenue reached $48.07 million, indicating strong performance
  • Trailing twelve months (TTM) revenue of $116.33 million shows consistent growth
  • Net income for the latest quarter was $65.34 million, reflecting robust profitability
Financial Highlights
  • Dividend yield of 10.29% offers attractive income potential
  • Price-to-earnings (P/E) ratio stands at 2.94, suggesting undervaluation
  • Market capitalization of approximately $603 million indicates solid market presence
Tekla Life Sciences Investors presents a compelling opportunity for investors interested in the life sciences sector. The fund's strategic focus on growth-oriented companies, combined with its strong financial performance, positions it well for future growth. The impressive dividend yield and favorable valuation metrics further enhance its appeal. Investors may find Tekla Life Sciences Investors an intriguing option for diversifying their portfolios within the dynamic life sciences industry.
AI Generated • Jul 22, 2026

Industry

Capital Markets

Sector

Financials

Website

www.teklacap.com/hql.html

Headquarters

Philadelphia, PA 02110, US

HQL Financials

Key Financial Metrics (TTM)

Gross Margin

90.69%

Operating Margin

331.92%

Net Income Margin

331.92%

Return on Equity

36.89%

Return on Capital

16.66%

Return on Assets

35.18%

Earnings Yield

33.90%

Dividend Yield

10.34%

Payout Ratio

25.13%

Stock Overview

Market Cap

$599.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

30.41M

Volume

7.21K

Avg. Volume

119.35K

Financials (TTM)

Gross Profit

$71.73M

Operating Income

$149.67M

EBITDA

$185.97M

Operating Cash Flow

-$3.54M

Capital Expenditure

-$4.00

Free Cash Flow

-$3.54M

Cash & ST Invst.

$851.60K

Total Debt

$0.00

Abrdn Life Sciences Investors Performance Analysis

Abrdn Life Sciences Investors annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30USD 31,862,397-29.2%
20232023-09-30USD 39,385,07223.6%
20242024-09-30USD 35,937,159-8.8%
20252025-09-30USD 29,832,339-17.0%
Abrdn Life Sciences Investors sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-30-7.3%
Q22025-03-31850.5%
Q42025-09-30-36.1%
Q22026-03-31313.2%
Abrdn Life Sciences Investors annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30USD -4.07N/A
20232023-09-30USD 0.83N/A
20242024-09-30USD 3.04264.3%
20252025-09-30USD 2.89-4.9%
Abrdn Life Sciences Investors sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-30-33.7%
Q22025-03-31-234.4%
Q42025-09-30380.5%
Q22026-03-31-53.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$48.07M

+2227.6%

Gross Profit

$44.95M

+2076.6%

Gross Margin

93.52%

N/A

Market Cap

$599.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

$65.34M

+30.0%

EBITDA

$65.34M

-35.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$851.60K

-93.8%

Total Debt

$0.00

N/A

Accounts Receivable

$1.27M

+1022.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

35.18%

N/A

Return on Invested Capital

35.24%

N/A

Free Cash Flow

-$1.22M

N/A

Operating Cash Flow

-$1.22M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GAINGladstone Investment Corp.
$16.30-1.45%
ECCEagle Point Credit Company Inc.
$3.71+0.00%
GLADGladstone Capital Corporation
$19.13-2.05%
CCAPCrescent Capital BDC, Inc.
$11.06-0.09%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$212.25+0.02%
NOKNokia
$10.28-0.03%
SPCXSpace Exploration Technologies
$115.31-0.07%
NUNu Holdings
$14.50+0.01%

Questions About HQL

What is the current price of Abrdn Life Sciences Investors?

Abrdn Life Sciences Investors is trading at $19.77 per share.

What is the 52-week range for Abrdn Life Sciences Investors?

Over the past 52 weeks, Abrdn Life Sciences Investors has traded between $13.01 and $21.32.

How much debt does Abrdn Life Sciences Investors have?

As of the most recent reporting period, Abrdn Life Sciences Investors reported total debt of $0.00.

How much cash does Abrdn Life Sciences Investors have on hand?

Abrdn Life Sciences Investors reported $75.54K in cash and cash equivalents in its most recent financial results.

What is Abrdn Life Sciences Investors’s dividend yield?

Abrdn Life Sciences Investors currently has a dividend yield of 10.34%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services